{
  "pathway_name": "acute-myeloid-leukemia-clinical-pathways-v2-2024",
  "original_file": "acute-myeloid-leukemia-clinical-pathways-v2-2024_extracted.json",
  "processed_at": "2025-03-29T01:18:15.663671",
  "complete_summary": {
    "response": "# COMPREHENSIVE CLINICAL PATHWAY: ACUTE MYELOID LEUKEMIA (AML)\n\n## DIAGNOSTIC EVALUATION\n\n### Required Initial Testing\n1. **Flow Cytometry**\n   - Leukemia/lymphoma panel\n   - Specimen: Bone marrow or peripheral blood\n   - Purpose: Lineage assignment, identification of abnormal populations\n\n2. **FISH (Fluorescence In Situ Hybridization)**\n   - Test for specific translocations: t(8;21), inv(16), t(15;17), BCR-ABL1, TP53\n   - Specimen: Bone marrow or peripheral blood\n\n3. **Conventional Karyotyping**\n   - Standard chromosome analysis\n   - Specimen: Bone marrow (preferred) or peripheral blood\n\n4. **Rapid Molecular Testing** (results required within 1 week)\n   - FLT3 (ITD and TKD), IDH1/2, NPM1, CEBPA (optional)\n   - Critical for initial treatment decisions\n\n### Advanced Genomic Profiling\n1. **Somatic NGS Panel**\n   - Essential genes: ASXL1, BCOR, CEBPA, EZH2, FLT3, IDH1, IDH2, NPM1, RUNX1, SF3B1, SRSF2, STAG2, TP53, U2AF1, ZRSR2\n   - Optional genes: CBL, DNMT3A, KIT, KRAS, NRAS, others associated with myeloid neoplasms\n\n2. **Comprehensive Genomic Profiling**\n   - Consider if no driver mutation detected in initial testing\n   - Available through Foundation Medicine with NPOP coverage\n\n3. **Germline Testing**\n   - Consider if VAF >40% in AML predisposition genes (CEBPA, DDX41, RUNX1, ANKRD26, ETV6, GATA2, SAMD9, SAMD9L, BLM, NF1, CBL)\n   - Requires genetic counseling\n   - Specimen: Peripheral blood only (not bone marrow)\n\n## RISK STRATIFICATION AND TREATMENT SELECTION\n\n### Assessment for Intensive Therapy Candidacy\n- Based on: Age, performance status, comorbidities, social factors\n- Determines primary treatment pathway\n\n## TREATMENT APPROACHES\n\n### A. FIRST-LINE THERAPY FOR INTENSIVE THERAPY CANDIDATES\n\n#### 1. FLT3-Mutated AML\n- **Induction**: Cytarabine (7 days) + daunorubicin/idarubicin (3 days) + midostaurin\n- **Response Assessment**: Bone marrow biopsy (typically day 14)\n- **Consolidation** (if response achieved):\n  * High-dose cytarabine (HiDAC) with midostaurin, or\n  * Allogeneic stem cell transplantation\n\n#### 2. FLT3 Wild-Type AML with Favorable Cytogenetics\n- **Induction**: Cytarabine (7 days) + daunorubicin/idarubicin (3 days)\n- **Response Assessment**: Bone marrow biopsy (day 14)\n- **Consolidation**: HiDAC, FLAG-IDA, or other cytarabine-based regimens\n\n#### 3. FLT3 Wild-Type AML with Intermediate Cytogenetics\n- **Induction**: Cytarabine (7 days) + daunorubicin/idarubicin (3 days)\n- **Response Assessment**: Bone marrow biopsy (day 14)\n- **Consolidation**:\n  * HiDAC\n  * FLAG-IDA\n  * Allogeneic stem cell transplantation (especially with high-risk features)\n  * Other cytarabine-based regimens\n\n#### 4. FLT3 Wild-Type AML with Poor/Adverse Cytogenetics\n- **Induction**: Cytarabine (7 days) + daunorubicin/idarubicin (3 days)\n- **Response Assessment**: Bone marrow biopsy (day 14)\n- **Consolidation**:\n  * Allogeneic stem cell transplantation (preferred)\n  * If transplant ineligible: HiDAC or clinical trial\n\n#### 5. Therapy-related AML, MDS-AML, or Complex Cytogenetics\n- **Induction**: CPX-351 (liposomal cytarabine-daunorubicin) where available\n- **Alternative**: Standard \"7+3\" regimen\n- **Consolidation**:\n  * Allogeneic stem cell transplantation (preferred)\n  * If transplant ineligible: additional CPX-351 cycles\n\n### B. FIRST-LINE THERAPY FOR NON-INTENSIVE THERAPY CANDIDATES\n\n1. **Preferred Regimen**:\n   - Decitabine (days 1-5 of 28-day cycle) + venetoclax (dose-escalated to 400mg daily)\n\n2. **Alternative Options**:\n   - Low-dose cytarabine + venetoclax\n   - Azacitidine + venetoclax\n   - Clinical trial\n   - Supportive care only (very poor prognosis or patient preference)\n\n3. **Response Assessment**:\n   - Bone marrow biopsy after cycle 1 (day 28)\n   - Subsequent assessments as clinically indicated\n\n## RELAPSED/REFRACTORY DISEASE MANAGEMENT\n\n### Initial Assessment at Relapse\n1. **Required Testing**:\n   - Flow cytometry (including CD33 expression)\n   - Myeloid NGS testing (minimum panel as specified above)\n   - Note: Relapse defined as recurrence >6 months after prior therapy\n\n2. **Prior Treatment History Assessment**:\n   - Prior allogeneic transplant?\n   - Prior therapy with HMA and venetoclax?\n   - Transplant candidacy assessment\n\n### Treatment Pathways for Relapsed AML\n\n#### 1. Patients with Prior Transplant\n- Discuss with cell therapy team for reinduction/consolidation options\n- Treatment: Decitabine + venetoclax as bridging therapy\n- Goal: Proceed to second allogeneic transplant if possible\n\n#### 2. Patients without Prior Transplant (Transplant Candidates)\n- Standard approach: Decitabine + venetoclax for reinduction\n- Goal: Proceed to allogeneic transplant\n\n#### 3. Patients without Transplant Options (Based on Molecular Subtype)\n\na. **IDH1 Mutation Positive**\n   - Shared decision-making options:\n     * Decitabine + venetoclax, or\n     * Ivosidenib\n\nb. **IDH2 Mutation Positive**\n   - Shared decision-making options:\n     * Decitabine + venetoclax, or\n     * Enasidenib\n\nc. **CD33 Expression Positive** (no other actionable targets)\n   - Shared decision-making options:\n     * Decitabine + venetoclax, or\n     * Gemtuzumab ozogamicin\n\nd. **FLT3 Mutation Positive**\n   - Preferred treatment: Gilteritinib\n\ne. **Other Molecular Subtypes**\n   - If prior HMA and venetoclax: Low-dose cytarabine + venetoclax\n   - If no prior HMA and venetoclax: Decitabine + venetoclax\n\n### Clinical Trial Consideration\n- Clinical trials should be considered at all decision points\n- Contact CancerClinicalTrialsNavigation@va.gov for assistance\n\n## SPECIAL CONSIDERATIONS\n\n### Venetoclax Therapy Management\n1. **Drug Interactions**\n   - Oncology pharmacist consultation recommended\n   - Dose adjustments required with CYP3A4 inhibitors\n\n2. **Cytopenia Management**\n   - Interrupt therapy for ANC <500/\u03bcL or platelets <25,000/\u03bcL\n   - Resume at reduced dose or with treatment-free intervals\n\n3. **Monitoring**\n   - Weekly CBC during first cycle\n   - Anti-infection prophylaxis for neutropenic patients\n   - Regular bone marrow biopsies for response assessment\n\n### IDH Inhibitors & Gilteritinib Monitoring\n1. **Differentiation Syndrome**\n   - Symptoms: Fever, dyspnea, pleural/pericardial effusions, pulmonary infiltrates, hypoxia, hypotension, weight gain, edema\n   - Management: Corticosteroids, supportive care, possible drug interruption\n\n2. **Response Evaluation**\n   - First assessment typically after 2 cycles\n   - Continue therapy in responding patients until progression or unacceptable toxicity\n\n## SUPPORTIVE CARE\n\n### Tumor Lysis Syndrome Prevention\n- Allopurinol and IV fluid prophylaxis\n- Rasburicase for high WBC, hyperuricemia, and/or renal dysfunction\n\n### Transfusion Support\n- Platelets for counts \u226410,000/mcL\n- RBC transfusion for hemoglobin \u22647 g/dL\n- Cryoprecipitate for fibrinogen <150mg/dL\n\n### Infection Prevention\n- Antifungal prophylaxis\n- HSV/VZV prophylaxis (acyclovir/valacyclovir)\n- Consider antibacterial prophylaxis during neutropenia\n\n## VA-SPECIFIC CONSIDERATIONS\n\n### Transplant and Cell Therapy\n- Pre-transplant evaluation required\n- Review through TRACER program\n\n### Genomic Testing Resources\n- Genomic Laboratory Advancement (GLA) program\n- National Precision Oncology Program (NPOP) coverage for advanced testing\n\n### Presumptive Service Connection\n- Veterans with exposure to ionizing radiation (Atomic Veterans)\n- All forms of leukemia (including AML) qualify under this presumption\n- Additional information: U.S. Department of Veterans Affairs - Presumptive Disability Benefits (va.gov)\n\n## RESPONSE ASSESSMENT DEFINITIONS\n\n- **Complete Remission (CR)**: <5% blasts in bone marrow, no extramedullary disease, ANC >1,000/\u03bcL, platelets >100,000/\u03bcL, independence from RBC transfusions\n- **Complete Remission with Incomplete Hematologic Recovery (CRi)**: As above but with persistent cytopenias\n- **Morphologic Leukemia-Free State (MLFS)**: <5% blasts in bone marrow, no extramedullary disease, cytopenias of any degree\n- **Partial Remission (PR)**: 5-25% blasts in bone marrow with \u226550% decrease from baseline",
    "thinking": "# Comprehensive Summary of Acute Myeloid Leukemia (AML) Clinical Pathway\n\nI'll create a comprehensive, structured clinical pathway document for Acute Myeloid Leukemia based on the detailed information provided. I'll organize this into logical sections covering diagnosis, risk stratification, treatment approaches for different patient populations, and management of relapsed disease.\n\n## OVERVIEW STRUCTURE\n1. Introduction/Purpose\n2. Diagnostic Evaluation\n3. Risk Stratification\n4. Treatment Approaches\n   - For Intensive Therapy Candidates\n   - For Non-Intensive Therapy Candidates\n5. Response Assessment\n6. Relapsed/Refractory Disease Management\n7. Special Considerations\n8. Supportive Care\n9. Appendices/References\n\nNow I'll elaborate each section with the detailed information provided:\n\n## 1. Introduction/Purpose\n\nThis clinical pathway provides evidence-based guidance for the diagnosis, evaluation, and management of Acute Myeloid Leukemia (AML). It is intended to standardize care while allowing for personalization based on patient-specific factors and evolving evidence.\n\n## 2. Diagnostic Evaluation and Initial Workup\n\n### Required Initial Diagnostic Testing\n\n1. **Flow Cytometry**\n   - Leukemia/lymphoma panel\n   - Specimen: Bone marrow aspirate or peripheral blood\n   - Purpose: Lineage assignment, identification of abnormal populations\n\n2. **FISH (Fluorescence In Situ Hybridization)**\n   - For detection of specific translocations:\n     - t(8;21) RUNX1:RUNX1T1\n     - inv(16)/t(16;16) CBFB:MYH11\n     - t(15;17) PML:RARA\n     - BCR-ABL1\n     - TP53 deletion/mutation\n   - Specimen: Bone marrow or peripheral blood\n\n3. **Conventional Karyotyping**\n   - Standard chromosome analysis\n   - Specimen: Bone marrow aspirate (preferred) or peripheral blood\n\n4. **Rapid Molecular Testing** (results required within 1 week)\n   - FLT3 ITD and TKD mutations\n   - IDH1/IDH2 mutations\n   - NPM1 mutations (quantitative preferred)\n   - CEBPA mutations (optional)\n   - Specimen: Bone marrow or peripheral blood\n\n### Advanced Genomic Profiling\n\n5. **Somatic NGS (Next Generation Sequencing)**\n   - Recommended gene panel:\n     - Essential genes: ASXL1, BCOR, CEBPA, EZH2, FLT3, IDH1, IDH2, NPM1, RUNX1, SF3B1, SRSF2, STAG2, TP53, U2AF1, ZRSR2\n     - Optional genes: CBL, DNMT3A, KIT, KRAS, NRAS, and other genes associated with myeloid neoplasms\n   - Specimen: Bone marrow or peripheral blood\n   - If no driver mutation detected, consider Comprehensive Genomic Profiling (CGP)\n\n6. **Germline Testing Considerations**\n   - Consider germline testing and genetic counseling if variant allele frequency (VAF) >40% is detected in AML predisposition genes:\n     - CEBPA, DDX41, RUNX1, ANKRD26, ETV6, GATA2, SAMD9, SAMD9L, BLM, NF1, CBL\n   - Specimen: Peripheral blood only (not bone marrow)\n\n## 3. Risk Stratification\n\nAML risk stratification incorporates cytogenetic and molecular findings to guide treatment intensity and approach.\n\n### Cytogenetic Risk Groups\n\n1. **Favorable Risk**\n   - t(8;21)(q22;q22.1); RUNX1-RUNX1T1\n   - inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11\n\n2. **Intermediate Risk**\n   - Normal karyotype without adverse-risk molecular features\n   - t(9;11)(p21.3;q23.3); MLLT3-KMT2A\n   - Other cytogenetic abnormalities not classified as favorable or adverse\n\n3. **Adverse/Poor Risk**\n   - Complex karyotype (\u22653 chromosomal abnormalities)\n   - Monosomal karyotype\n   - t(6;9)(p23;q34.1); DEK-NUP214\n   - t(v;11q23.3); KMT2A rearrangements\n   - t(9;22)(q34.1;q11.2); BCR-ABL1\n   - inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)\n   - -5 or del(5q); -7; -17/abn(17p)\n\n### Molecular Risk Groups\n\n1. **Favorable Risk**\n   - NPM1 mutation without FLT3-ITD or with FLT3-ITDlow\n   - Biallelic CEBPA mutation\n\n2. **Intermediate Risk**\n   - NPM1 mutation with FLT3-ITDhigh\n   - Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without adverse-risk genetic lesions)\n\n3. **Adverse/Poor Risk**\n   - TP53 mutation\n   - RUNX1 mutation (in absence of favorable features)\n   - ASXL1 mutation (in absence of favorable features)\n   - Wild-type NPM1 with FLT3-ITDhigh\n\n### Additional Factors for Treatment Intensity Determination\n\nAssessment for intensive therapy candidacy based on:\n- Age\n- Performance status\n- Comorbidities\n- Social factors\n\n## 4. Treatment Approaches\n\n### A. For Intensive Therapy Candidates\n\n#### FLT3-Mutated AML\n\n1. **Induction Therapy**\n   - Standard \"7+3\" regimen:\n     - Cytarabine (100-200 mg/m\u00b2 continuous IV infusion, days 1-7)\n     - Daunorubicin (60-90 mg/m\u00b2 IV, days 1-3) or idarubicin (12 mg/m\u00b2 IV, days 1-3)\n     - PLUS midostaurin (50 mg PO BID, days 8-21)\n   \n2. **Response Assessment**\n   - Bone marrow biopsy typically on day 14\n   - For cytoreduction failure: consider salvage options\n   \n3. **Consolidation Therapy (if response achieved)**\n   - Option 1: High-dose cytarabine (HiDAC) with midostaurin\n   - Option 2: Allogeneic stem cell transplantation (for eligible patients)\n\n#### FLT3 Wild-Type AML with Favorable Cytogenetics\n\n1. **Induction Therapy**\n   - Standard \"7+3\" regimen:\n     - Cytarabine (100-200 mg/m\u00b2 continuous IV infusion, days 1-7)\n     - Daunorubicin (60-90 mg/m\u00b2 IV, days 1-3) or idarubicin (12 mg/m\u00b2 IV, days 1-3)\n   \n2. **Response Assessment**\n   - Bone marrow biopsy typically on day 14\n   - For cytoreduction failure: consider salvage options\n   \n3. **Consolidation Therapy (if response achieved)**\n   - High-dose cytarabine (HiDAC)\n   - Alternatives: FLAG-IDA or other cytarabine-based regimens\n\n#### FLT3 Wild-Type AML with Intermediate Cytogenetics\n\n1. **Induction Therapy**\n   - Standard \"7+3\" regimen:\n     - Cytarabine (100-200 mg/m\u00b2 continuous IV infusion, days 1-7)\n     - Daunorubicin (60-90 mg/m\u00b2 IV, days 1-3) or idarubicin (12 mg/m\u00b2 IV, days 1-3)\n   \n2. **Response Assessment**\n   - Bone marrow biopsy typically on day 14\n   - For cytoreduction failure: consider salvage options\n   \n3. **Consolidation Therapy (if response achieved)**\n   - Option 1: High-dose cytarabine (HiDAC)\n   - Option 2: FLAG-IDA regimen\n   - Option 3: Allogeneic stem cell transplantation (especially for high-risk features)\n   - Option 4: Other cytarabine-based regimens\n\n#### FLT3 Wild-Type AML with Poor/Adverse Cytogenetics\n\n1. **Induction Therapy**\n   - Standard \"7+3\" regimen:\n     - Cytarabine (100-200 mg/m\u00b2 continuous IV infusion, days 1-7)\n     - Daunorubicin (60-90 mg/m\u00b2 IV, days 1-3) or idarubicin (12 mg/m\u00b2 IV, days 1-3)\n   \n2. **Response Assessment**\n   - Bone marrow biopsy typically on day 14\n   - For cytoreduction failure: consider salvage options\n   \n3. **Consolidation Therapy (if response achieved)**\n   - Allogeneic stem cell transplantation (preferred)\n   - If transplant ineligible: High-dose cytarabine (HiDAC) or clinical trial\n\n#### Therapy-related AML or MDS-AML with Adverse Risk or Complex Cytogenetics\n\n1. **Induction Therapy**\n   - CPX-351 (liposomal cytarabine-daunorubicin) where available\n   - Alternative: Standard \"7+3\" regimen\n   \n2. **Response Assessment**\n   - Bone marrow biopsy typically on day 14\n   - For cytoreduction failure: consider salvage options\n   \n3. **Consolidation Therapy (if response achieved)**\n   - Allogeneic stem cell transplantation (preferred)\n   - If transplant ineligible: additional CPX-351 cycles or clinical trial\n\n### B. For Non-Intensive Therapy Candidates\n\n1. **Preferred Regimen**\n   - Decitabine (20 mg/m\u00b2 IV, days 1-5 of 28-day cycle) and venetoclax (ramp-up to 400 mg daily PO)\n   \n2. **Alternative Options**\n   - Low-dose cytarabine + venetoclax\n   - Azacitidine + venetoclax\n   - Clinical trial\n   - Supportive care only for patients with very poor prognosis or patient preference\n\n3. **Response Assessment**\n   - Bone marrow biopsy typically after cycle 1 (day 28)\n   - Subsequent bone marrow assessments as clinically indicated\n\n## 5. Response Assessment and Monitoring\n\n### Response Definitions\n\n1. **Complete Remission (CR)**\n   - <5% blasts in bone marrow\n   - No evidence of extramedullary disease\n   - ANC >1,000/\u03bcL\n   - Platelets >100,000/\u03bcL\n   - Independence from RBC transfusions\n\n2. **Complete Remission with Incomplete Hematologic Recovery (CRi)**\n   - <5% blasts in bone marrow\n   - No evidence of extramedullary disease\n   - ANC <1,000/\u03bcL and/or platelets <100,000/\u03bcL\n\n3. **Morphologic Leukemia-Free State (MLFS)**\n   - <5% blasts in bone marrow\n   - No evidence of extramedullary disease\n   - Cytopenias of any degree\n   - May have persistent dysplasia\n\n4. **Partial Remission (PR)**\n   - 5-25% blasts in bone marrow with \u226550% decrease from baseline\n   - ANC >1,000/\u03bcL\n   - Platelets >100,000/\u03bcL\n\n### Bone Marrow Biopsy Monitoring Schedule\n\n1. **After Induction**\n   - Typically day 14 for intensive therapy\n   - Day 21-28 for non-intensive therapy\n\n2. **After Consolidation**\n   - Typically 21-28 days after completion of each consolidation cycle\n\n3. **Follow-up Period**\n   - Every 3 months for 2 years\n   - Every 6 months for years 3-5\n   - Annually thereafter, or as clinically indicated\n\n## 6. Relapsed/Refractory Disease Management\n\n### Initial Assessment\n\n1. **Required Testing at Relapse**\n   - Flow cytometry (including CD33 expression)\n   - Myeloid NGS testing (minimum panel must include: ASXL1, BCOR, CEBPA, EZH2, FLT3, IDH1, IDH2, NPM1, RUNX1, SF3B1, SRSF2, STAG2, TET2, U2AF, ZRSR2)\n   - Note: Relapse defined as recurrence >6 months after prior therapy\n\n2. **Prior Treatment History Assessment**\n   - Prior allogeneic transplant? (Yes/No)\n   - Prior therapy with hypomethylating agent (HMA) and venetoclax? (Yes/No)\n   - Transplant candidacy assessment\n\n### Treatment Approaches Based on Prior Treatment and Molecular Features\n\n#### Patients with Prior Transplant\n\n1. **Initial Step**\n   - Discuss with cell therapy team for reinduction/consolidation options\n   \n2. **Treatment Approach**\n   - If eligible for cellular therapy: Refer to cell therapy team\n   - Standard bridging approach: Decitabine and venetoclax\n   - Goal: Proceed to second allogeneic transplant if possible\n\n#### Patients without Prior Transplant (and Transplant Candidates)\n\n1. **Standard Approach**\n   - Decitabine and venetoclax as reinduction therapy\n   - Goal: Proceed to allogeneic transplant\n\n#### Patients without Transplant Options (Based on Molecular Subtype)\n\n1. **IDH1 Mutation Positive**\n   - Shared decision-making options:\n     - Option A: Decitabine and venetoclax\n     - Option B: Ivosidenib\n\n2. **IDH2 Mutation Positive**\n   - Shared decision-making options:\n     - Option A: Decitabine and venetoclax\n     - Option B: Enasidenib\n\n3. **CD33 Expression Positive** (in absence of other actionable targets)\n   - Shared decision-making options:\n     - Option A: Decitabine and venetoclax\n     - Option B: Gemtuzumab ozogamicin\n\n4. **FLT3 Mutation Positive**\n   - Preferred treatment: Gilteritinib\n\n5. **Other Molecular Subtypes**\n   - If prior HMA and venetoclax: Low-dose cytarabine + venetoclax\n   - If no prior HMA and venetoclax: Decitabine and venetoclax\n\n### Clinical Trial Consideration\n\n- Clinical trials should be considered at all decision points\n- Contact CancerClinicalTrialsNavigation@va.gov for assistance with trial identification\n\n## 7. Special Considerations\n\n### Venetoclax Therapy Management\n\n1. **Drug Interactions**\n   - Oncology pharmacist consultation recommended\n   - Dose adjustments for CYP3A4 inhibitors:\n     - Strong inhibitors: Reduce venetoclax to 100 mg\n     - Moderate inhibitors: Reduce venetoclax to 200 mg\n\n2. **Dose Adjustments for Cytopenias**\n   - For ANC <500/\u03bcL or platelet count <25,000/\u03bcL:\n     - Interrupt therapy until count recovery\n     - Resume at reduced dose or with treatment-free intervals\n\n3. **Monitoring**\n   - Weekly CBC during first cycle\n   - Anti-infection prophylaxis for neutropenic patients\n   - Regular bone marrow biopsies for response assessment\n\n### IDH Inhibitors & Gilteritinib Considerations\n\n1. **Differentiation Syndrome Monitoring**\n   - Symptoms: Fever, dyspnea, pleural/pericardial effusions, pulmonary infiltrates, hypoxia, hypotension, rapid weight gain, peripheral edema\n   - Management: Corticosteroids, hemodynamic monitoring, respiratory support\n   - May require temporary drug interruption\n\n2. **Response Evaluation**\n   - First assessment typically after 2 cycles\n   - Continue therapy in responding patients until progression or unacceptable toxicity\n\n### VA-Specific Services and Programs\n\n1. **VA Transplant Program**\n   - Pre-transplant evaluation required\n   - TRACER program review process\n\n2. **VA Genomic Testing Resources**\n   - Genomic Laboratory Advancement (GLA) program available\n   - National Precision Oncology Program (NPOP) coverage for some advanced testing\n\n## 8. Supportive Care\n\n### Tumor Lysis Syndrome (TLS) Prevention and Management\n\n1. **Prophylaxis**\n   - Allopurinol and IV fluids for standard risk\n   - Rasburicase for patients with high WBC, hyperuricemia, and/or renal dysfunction\n   - TLS monitoring: Electrolytes, uric acid, creatinine, LDH\n\n### Transfusion Support\n\n1. **Platelet Transfusion**\n   - Threshold: Platelet count \u226410,000/mcL\n   - Higher thresholds for active bleeding or planned procedures\n\n2. **RBC Transfusion**\n   - Threshold: Hemoglobin \u22647 g/dL\n   - Consider higher threshold for symptomatic patients\n\n3. **Coagulation Management**\n   - Cryoprecipitate for fibrinogen <150mg/dL\n\n### Infection Prevention\n\n1. **Antifungal Prophylaxis**\n   - For neutropenic patients during intensive chemotherapy\n   - Posaconazole preferred for intensive induction (consider drug interactions with venetoclax)\n   - Fluconazole for lower-risk patients\n\n2. **Antiviral Prophylaxis**\n   - HSV/VZV prophylaxis with acyclovir or valacyclovir\n\n3. **Antibacterial Prophylaxis**\n   - Fluoroquinolone during profound neutropenia (consider institutional resistance patterns)\n\n## Appendix: Acute Myeloid Leukemia - VA Presumptive Conditions\n\nThe VA automatically presumes certain disabilities were caused by military service based on specific circumstances of service.\n\n**Specific Presumptive Group:**\n- Atomic Veterans \u2013 Veterans with exposure to ionizing radiation\n- All forms of leukemia (including Acute Myeloid Leukemia) qualify under this presumption\n\nFor more information: U.S. Department of Veterans Affairs - Presumptive Disability Benefits (va.gov)"
  }
}